McGill University Health Centre

Montréal, QC

Accepting patients

AZD0305

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/​Refractory Multiple Myeloma
Learn more
  • PARP Inhibitor
  • Phase 1/2

Not yet accepting

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3